Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$8.90 USD
-0.44 (-4.71%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $8.91 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRBP 8.90 -0.44(-4.71%)
Will CRBP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBP
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
3 Unconventional Cannabis Stocks to Watch in 2025
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
Other News for CRBP
Corbus Pharmaceuticals (CRBP) Gears Up for Pivotal Data Presentations in Late 2025
Corbus Pharmaceuticals GAAP EPS of -$1.44 misses by $0.08
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate ...
Corbus Pharmaceuticals reports Q2 EPS ($1.44), consensus ($1.33)
CRBP: B. Riley Maintains Buy Rating with Promising Drug Potential